TUCSON, Ariz. — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, announced the availability of the HTG EdgeSeq Immuno-Oncology Assay (research use only) for digitally measuring the mRNA expression of 549 genes implicated in the host immune response to tumors. Automated on the HTG EdgeSeq system, HTG EdgeSeq Immuno-Oncology Assay couples HTG’s proprietary nuclease protection chemistry with next-generation sequencing (NGS).

“With this new immuno-oncology assay, researchers can measure the expression levels of drug targets, determine tumor infiltrate composition, and assess total immune cell composition using just a single section of FFPE tissue,” stated Chris Roberts, HTG’s Senior Vice President of Marketing and Medical Innovation. “We believe the expanding trend in the development of immuno-oncology therapies will continue, and this new assay can be a valuable tool in the research of tumor biomarkers in tissue and liquid biopsies.”

“HTG Molecular is proud to be at the forefront of this new product category,” commented TJ Johnson, HTG’s Chief Executive Officer. “We continue to believe that the combination of HTG’s extraction free sample and library preparation chemistry automated on the HTG EdgeSeq system with NGS quantitation is providing our customers with powerful new capabilities,” Mr. Johnson added.

About HTG Molecular Diagnostics:

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.